SecBot SecBot
SECBOTREPLAY Home › Report › NVS

NVS · Novartis announced positive Phase III topline results for remibrutinib…

NOVARTIS AG · 6-K filed Sep 1, 2026 at 06:21 ET

At the news

BULLISHIMPACT 7/10

6-K filed Sep 1, 2026 at 06:21 ET

Novartis announced positive Phase III topline results for remibrutinib in relapsing multiple sclerosis (RMS). The REMODEL-1 and REMODEL-2 trials met their primary endpoint of significantly reducing annualized relapse rate (ARR) versus teriflunomide, with superiority on all key secondary endpoints including MRI lesions and disability progression. The safety profile was favorable with no liver safety signal. Novartis plans to present the data at MSToronto2026 and seek global regulatory approval. This expands remibrutinib's pipeline beyond its already-approved CSU indication (Rhapsido), representing a significant pipeline catalyst for a large-market indication (RMS affects nearly 3 million people worldwide). No financial figures were provided in the filing.

  • REMODEL-1/-2 Phase III trials met primary endpoint: significantly reduced annualized relapse rate (ARR) vs teriflunomide in relapsing multiple sclerosis (RMS)
  • Remibrutinib showed superiority on all key secondary endpoints, including reduction of MRI lesions and clinically meaningful delay in disability progression
  • Favorable safety profile consistent with broader development program (>4,500 participants), with no liver safety signal
  • Novartis plans to present late-breaking data at MSToronto2026 and submit to health authorities globally

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access